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The ability to determine  
the non-transferrin-bound iron  
and total iron in the human placenta 
using high-performance liquid 
chromatography method
AbsTrAcT
Iron is one of the most important microelements in the human body. It is a component of haemoglobin, 
which transports oxygen to all cells in the organism. It is also used in the synthesis of myelin, neurotrans-
mitters, and DNA and transfers electrons in biochemical reactions. Iron is also responsible for regular 
development of the foetus’ central nervous system. Furthermore, as a result of Fenton reactions, iron leads 
to formation of toxic free radicals. The existence of non-transferrin-bound iron (NTBI) and its part desfer-
rioxamine-chelatable iron (DCI) can be used to assess this element in the body. The placenta is an organ 
transition that is formed during pregnancy in the female organism. It has a dense web of blood vessels in 
which dynamic exchange of blood between mother and foetus takes place. As a result, a fraction of NTBI 
may be present in the placenta. The main goal of this work was to develop a method for determining total 
iron and desferrioxamine-chelatable iron in solid tissues - the human placenta.
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Introduction
iron is a necessary component for the body to func-
tion properly. this basic microelement plays an integral 
role in most biochemical and metabolic processes 
in the human organism. iron is a substrate for heme 
synthesis, it participates in the oxidation-reduction, 
immune reaction, and DNa synthesis [1]. Biological 
functions of iron include transportation and detection 
of diatomic gases and electrons transfer. therefore, 
the human organism needs iron to transport oxygen 
to tissues and for electron transport in the Krebs cycle 
[2]. iron in the body may be present on two oxidation 
levels: Fe+2 and Fe+3. it is a central component of heme 
- prosthetic group in haemoglobin, myoglobin, peroxi-
dase, catalase, cytochrome c, and other proteins. total 
metabolically active iron is contained in 70% in heme, 
20% in ferritin, and 10% in enzymes, and only 0.15% of 
iron is bound to transferrin. as previously mentioned, 
iron is mainly bound to protein, which is associated with 
its functions in the organism. Furthermore, in the human 
body there is also another form of iron: non-transfer-
rin-bound iron (NtBi). the appearance of NtBi and 
its component – desferrioxamine-chelatable iron (Dci) 
– can be used for rating this element in the body [3–4]. 
iron is toxic when it is present in abundance, so 
tight regulation is very important to avoid overload or 
deficiency of iron. the human organism is not a de-
veloped mechanism that removes iron from the body 
when it is overloaded. losses of this component take 
place through intestinal secretions, desquamated 
epithelium, and also during menstruation in women. 
several current researchers indicate the participation 
of severe untreated iron overload in the pathogenesis 
of diseases such as fibrosis and cirrhosis of the liver, 
diabetes, hypothyroidism, hypogonadism, and cardiac 
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arrhythmias. currently researchers are focusing on 
analysing the effects of less pronounced grades of iron 
overload in the development of chronic diseases [2].
iron is also responsible for the regular development 
of the foetus’ central nervous system. it is directly in-
volved in production and proper functioning of myelin 
and nerve fibres [9]. Prenatal iron deprivation can inhibit 
the synthesis of nervonic acid. this can result in abnor-
malities in myelination of the axons. iron deficiency also 
causes reduced activity of cytochrome c oxidase and 
alterations in metabolism of dopamine, serotonin, and 
other neurotransmitters [9–10]. Previous studies sug-
gest that iron deficiency in the initial period of life affects 
brain and behavioural functions that persist despite the 
use of iron [11]. the average iron content in a foetus 
weighting 3500 g in the third trimester of pregnancy is 
7.5 mg / 100 g body weight [10].
the damaging effect of NtBi is associated with its 
ability to take part in the Fenton reaction, which may 
result, among others, in cellular membrane damage 
and induce apoptosis [3]. Previous studies have re-
ported that NtBi is not detected in the serum of the 
healthy population [4,12]. the group most vulnerable 
to disorders caused by NtBi are newborns. NtBi is an 
indicator of the severity of intrauterine oxidative pro-
cesses and brain damage in newborns. Buonocore et 
al. demonstrated that an NtBi cord blood concentration 
higher than 15.2 μmol/l is the best and earliest marker 
of central nervous system damage in this group [5–6]. 
Determination of NtBi has the potential to be an effi-
cient method in the diagnosis of diseases associated 
with iron accumulation. another important finding was 
that inflammatory mediators do not affect NtBi level (in 
contrast to routinely determined parameters such as 
saturation of transferrin or ferritin concentration) [13]. 
the presence of the carbonyl group on albumin and 
a-fetoprotein in newborns with high concentration of 
NtBi was revealed. this demonstrates the intensified 
process of reactive oxygen species formation. Previous 
studies confirm that premature infants have increased 
concentrations of NtBi and products of protein and lipid 
oxidation than infants born at term. NtBi was also found 
in the amniotic fluid during physiological pregnancy 
and in about 25% of healthy newborns’ serum [14–15].
the placenta is an organ transition that is formed 
during pregnancy in the female organism. Probably the 
highest concentration of iron occurs in the placenta, 
where we observe a dense web of blood vessels and 
where intensive exchange of metabolites between 
mother and foetus takes place. For this reason, the 
fraction of NtBi may be present in the placenta. the 
iron level so far has been studied primarily in the serum. 
there are no studies on the level of iron in solid tissue 
such as placenta. iron deficiency can cause premature 
birth, low birth weight, infant developmental delays, 
and even infant death [2,7–8].  the effects of excess 
iron concentration in the foetus are not well known yet. 
this study presented a method for determination of iron 
concentration in the placenta.
the main aim of this study was to develop a meth-
od for determining NtBi and total iron in solid tissues 
and verification of the presence of these substances in 
human placenta. iron analysis has been made by high 
performance liquid chromatography (hPlc). the study 
took into consideration 13 placentas from physiologi-
cal pregnancy.
Experimental
chemicals or Reagents
Desferrioxamine (DFO) as Desferal® (Deferoxamini 
mesilas, N-[5-[3-[(5-aminopentyl)hydroxy-carbamoyl]
propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)
pentyl] carbamoyl] propionohydroxamic acid mono-
methanesulphonate) was from Novartis international 
aG (Basel, switzerland). hPlc-grade acetonitrile and 
water were from POch (Gliwice, Poland), and tris-hcl 
was from sigma-aldrich (Poznań, Poland).
apparatus
a shimadzu high-Performance liquid chroma-
tography set (Kyoto, Japan) equipped with vacuum 
degasser (DGU-20a5), solvent pump (lc-20aD), 
autosampler (sil-20aD), diode array detector (sPD-
M20a), column oven (ctO-20ac), communications 
bus module (cBM-20a), and lc solution software (ver. 
1.0.0.1 Kyoto, Japan) was used for complex hPlc 
analysis. an MPW-350R centrifuge (Med. instruments 
cooperative, Warsaw, Poland) was used for serum 
sample preparation. an hPlc octadecylsilane (c18) 
column candeza cD-c18 150x4.6 mm i.d., with par-
ticle size 3.0 μm (imtakt corporation, Kyoto, Japan) 
equipped with a pre-column analytical guard cartridge 
system KJ0–4282 (Phenomenex, torrance, ca, Usa) 
were used for chromatographic separation.
Preparation of placenta samples for determination 
of total iron and iron chelated by desferrioxamine
sample preparation is a particularly important step 
in the analysis of the placenta, and it differs from the 
process of preparation of other types of tissues such 
as serum. Before tissues were analysed by hPlc 
they required prior preparation composed of several 
steps. initially the placenta was homogenised. the first 
stage of homogenisation was tissue grinding in a mor-
tar. Next, homogenisation was performed in a liquid 
nitrogen atmosphere, until homogeneous mass was 
obtained. then cellular structures were broken down 
using tris-hcl buffer (ph = 8.5) and a 10% solution of 
triton X-100. subsequently, material was centrifuged 
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Figure 1. Representative chromatograms of total iron (150 μM concentration) on cadenza column in 8.5 ph
and then the mixture was incubated in a refrigerator 
for 12 h. after that time, samples were centrifuged and 
the supernatants of each sample were pipetted to ep-
pendorf. the next step was heating denaturation. this 
process resulted in the release of iron from proteins. For 
this purpose, samples were incubated in a thermocy-
cler for 20 minutes at 90°c. after this time, tubes were 
immediately transferred to ice for one minute. Next, 
the samples were centrifuged and the supernatants of 
each sample were pipetted to eppendorf. Furthermore, 
the sample was purified on columns. the columns 
prevented impurities. after centrifugation the removed 
impurities and the resultant filtrate was used for further 
studies. the filtrate obtained from each placenta was 
mixed 1:1 with a solution of desferrioxamine. after 
standing for two hours in the dark, Dci complexes were 
formed. chromatographic analysis was then performed 
on total iron and iron chelated by desferrioxamine in 
each of the placentas. to make results more reliable, 
some of the samples, before adding a solution of des-
ferrioxamine, were supplemented with solutions of iron 
(iii) at concentrations of 80 μM.
Preparation of calibration curve 
the quantitative measurement was performed using 
the RP-hPlc method. chromatographic separation was 
performed by gradient elution using a cadenza cD-
c18 column with solvent 10 mM tris-hcl and solvent 
acetonitrile-acN on the basis of a previously reported 
study by Koba et al. [3]. the step-form gradient elution 
conditions were optimised experimentally with a total 
run time of 15 min and with gradient changes in time of 
the hPlc analysis as follows: 15% during 0–1 min, 45% 
during 1–5 min, and 15% during 5–15 min. the retention 
times of FO indicated on Dci or total iron concentration 
were repeatably near 2.1 min (for representative chro-
matograms see Figures 1 and 2).
results and discussions
human placenta is a solid tissue, and it is a chal-
lenge to use this as material for hPlc analysis. to 
ensure reliable and accurate measurements, proper 
sample preparation is very important. in reviewing the 
literature, no description of this process in solid tissue 
was found. analyses in 10 samples of human placenta 
on a cadenza c18 column were performed. all mea-
surements were performed twice, and high repeatability 
was reported. table 1 presents average values of all re-
sults. table 1 presents the calculated concentrations of 
total iron in human placenta. the calculations are based 
on the equations of a calibration curve at 8.5 ph. sam-
ples of placenta were supplemented with solutions of 
iron at concentrations of 80 μM in order to make results 
more reliable. this allowed us to calculate a recovery 
[%] and interpret the results or assess the accuracy of 
the method. table 1 also presents the results of calcu-
lated total iron concentration after supplementation and 
calculated recovery. 
another parameter measurement in human placenta 
by hPlc was desferrioxamine-chelatable iron (Dci). it 
is a component of serum non-transferrin-bound iron 
(NtBi). table 1 shows Dci concentrations calculated 
by calibration curve (average value). a previous study 
of ours indicated that ph changes affect the number 
of Dci-formed complexes. therefore, the results of the 
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Figure 2. Representative chromatograms of Dci (50 μM concentration) on cadenza column in 8.5 ph.
Table 1. Results and recovery of total iron and Dci assays in placenta samples.
Number Total iron concentration  
in human placenta [μM]
Total iron supplemented  
(80 μM) concentration [μM]
Recovery [%] DCI concentration  
in human placenta [μM]
1 11.77 88.82 111% 9.77
2 13.21 88.56 111% 5.25
3 11.60 86.80 109% 3.48
4 11.45 89.07 111% 2.42
5 9.14 84.57 106% 1.63
6 12.71 89.47 112% 8.92
7 11.12 90.62 113% 9.48
8 10.66 90.56 113% 4.31
9 11.99 89.03 111% 5.03
10 11.25 87.19 109% 3.65
analysis should be related to a calibration curve with 
the same ph (in this study - 8.5 ph). Measurement on 
a cadenza column demonstrated a high repeatability. 
Results of Dci concentration were in range of 1.6-9.8 μM 
whereas total iron concentration ranged from 9.14 μM 
to 13.20 μM.
as mentioned, in the literature review we noted 
a lack of data about norms of Dci and total iron con-
centration and about different methods of measurement 
of this parameter in human placenta. in this study, the 
presence of Dci and total iron in human placenta was 
demonstrated. all measurements were performed twice, 
and high repeatability was reported. the potential of 
application this method for sample preparation and 
analysis of Dci and total iron measurement in solid 
tissue after previous optimisation and improvement 
was presented. therefore, the presented method may 
be used for routine assay of desferrioxamine-chelatable 
and/or total iron fractions in solid biological samples.
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